NT-0796 is an oral, brain-penetrant NLRP3 inhibitor that selectively regulates chronic inflammation, a key driver of cardiometabolic diseases ...
Lynkuet is the first FDA-approved therapy that blocks both the neurokinin 1 and neurokinin 3 receptors to treat hot flashes.
On Friday, the FDA approved Bayer’s dual neurokinin (NK) targeted therapy elinzanetant, which will now be marketed in the U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback